EP PerMed - European Partnership for Personalized Medicine

The European Partnership for Personalized Medicine (EP PerMed), co-funded by the European Union under Horizon Europe, is a platform for the joint programming of national and European research and innovation support activities that put into action the Strategic Research and Innovation Agenda (SRIA) for Personalized Medicine (2023)", SRIA for PM (2023), through dedicated funding for research, development and innovation.

Personalized Medicine is broadly understood as a medical model that uses the characterization of people's phenotypes and genotypes (e.g. molecular profiling, medical imaging, lifestyle data) to adjust the therapeutic strategy to each person at the right time, and/or to determine predisposition to diseases and/or to provide timely and appropriately targeted preventive care (according to the conclusions of the Council of the European Union on personalized medicine for patients - 2015/C 421/03).

EP PerMed brings together ministries, funding organizations and research institutes from 24 countries and 10 European regions, including the FCT, the Centro Regional Coordination and Development Commission, and the Regional Directorate for Science and Technology of the Regional Government of the Azores. The Partnership is based on the results and experience of various international initiatives and projects in the field of Personalized Medicine, as well as more than 15 years of successful collaboration between many of the partners involved. Over the next ten years (2023-2033), most of the EP PerMed budget will be available to fund research projects and the implementation of personalized medicine approaches.

In 2024, EP PerMed will launch its first joint transnational Call , PMTargets.

This initiative has received funding from the European Union's Horizon Europe research and innovation program, grant agreement No. 101137129.